Malaria Vaccines Market, By Vaccines Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, Multi-antigen Vaccine), Agent (Plasmodium Falciparum, Plasmodium Vivax), Distribution Channel (Hospitals, Clinics, Community Centers), and Geography - Insights, Opportunity Analysis, and Industry Forecast 2024 - 2027

  • Published On : Aug 2019 |
  • Pages : 158 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Malaria Vaccines – Paving the Way for a Malaria-free World

Nearly half of the global population is at risk of malaria as per stats released by the World Health Organization (WHO). This in turn has led to increased inclination of various healthcare agencies towards addressing this major malady. Global non-profit organizations such as the Melinda Gates Foundation and PATH are working towards developing preventive measures and saving lives of many in the malaria affected regions. Africa accounts for the 90% of malaria cases and hence, this region is the primary target of launching the first malaria vaccine developed by GlaxoSmithKline plc. Mosquirix received EU approval in 2015 and is presently being examined in Africa as a pilot study.

People in Africa use insecticide-treated mosquito nets and indoor-insecticide spraying for prevention against malarial vectors. Use of insecticide-treated mosquito nets in Africa increased by 80% during 2010-2015 (WHO). Moreover, a number of mosquito repellent products (patches, creams, coils, mats, liquids, etc.) are marketed globally. Besides, non-profit organizations provide cheap and often free treatment facilities to the malarial affected population in Africa. Also, GSK has pledged to sell the vaccines at a much lower cost forgoing its huge profit margins to support the global malaria eradication programs. Furthermore, with more malarial vaccines under research pipeline, the malaria vaccines market is poised for significant growth in near future.

The global malaria vaccines market is expected to be valued at US$ 50.6 million in 2024 and is expected to witness a CAGR of 150.0% during the forecast period (2024 – 2027).

Figure 1. Global Malaria Vaccines Market, Product Pipeline

Malaria Vaccines  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2019)

Tremendous potential in the malaria vaccines market

Potential for malaria vaccines is estimated to be huge as a large share of population, 90%-95%, at risk of infection in Africa and South East-Asia. Advent of vaccines for adult population, would be a major breakthrough for the malaria vaccines market. Below are certain alarming statistics that embarks the need for a malaria vaccine:

  • Artemisinin resistance has been detected in five countries – Laos, Cambodia, Myanmar, Vietnam and Thailand
  • Resistance to P. falciparum parasite against the most available anti-malarial medicines is being reported
  • According to the National Vector Borne Disease Control Programme, nearly 95% of the population in India reside in malaria endemic areas
  • There were 216 million malaria cases globally in 2016 (WHO)
  • Africa is the most affected region with 90% of malaria cases and deaths worldwide (WHO)
  • Pregnant women, children below 5 years of age, and tourists from countries with low incidence rate of malaria are identified as the most susceptible target population for malaria

The global malaria vaccines market is expected to experience a huge trajectory growth with the launch of first malarial vaccine in near future.

Increasing accessibility and government support to contribute towards the malaria vaccines market growth

The WHO has established a Global Technical Strategy for Malaria 2016-2030 (GTS) in 2015 with certain defined goals, one of them aimed at eliminating malaria in at least 10 countries. Similarly, the Indian government has established Drug Distribution Centers (DDCs) and Fever Treatment Depots (FTDs) in the rural areas for providing easy access to anti-malarial drugs. Regular monitoring and surveillance by various government programs has helped to reduce malarial cases in India from 2.03 million in 2010 to 1.1 million in 2015. Support from such national and global initiatives will drive malaria vaccines market growth during the forecast period.

Many such non-profit organizations and pharmaceutical companies are conducting research on malaria vaccines. Approximately 31 trials are under progress for malaria vaccine development with a few being blood stage projects. Availability of funds and government support programs will encourage commercialization of product with successful trial results, thus boosting the malaria vaccines market growth trajectory.

Malaria is a severe and widespread disease caused by a parasitic infection by protozoan Plasmodium when transmitted by various species of anopheles mosquitoes. In 2009, according to WHO, 214 Mn to 397 Mn clinical malaria cases were reported worldwide. However, high estimates of around 515 Mn clinical cases of P. falciparum were projected in 2002. Furthermore, malaria accounted for around 3% of the world’s total Disability Adjusted Life Years (DALYs) lost and around 10% in Africa alone. According to Centers for Disease Control and Prevention (CDC), there are around 156 types of Plasmodium species that infect various species of vertebrates. Among the numerous plasmodium species, four are considered true parasites of humans, as they utilize humans almost exclusively as a natural intermediate host: P. falciparum, P. vivax, P. ovale and P. malariae. Over 85% of malaria mortality is due to P. falciparum. Around 90% of deaths caused by malaria in Sub-Saharan Africa is primarily due to P. falciparum.

Market Dynamics

The growing incidence of malaria globally and major players pledging for low profit margin over vaccines is expected to boost growth of the malaria vaccines market. According to World Health Organization (WHO), in 2015, approximately 292,000 children in Africa died of malaria, at very early age of 5 years. Around 306,000 fatalities associated with malaria were reported worldwide in 2015, out of which around 90% cases were reported in Africa.

According to World Health Organization (WHO), first global malaria vaccines has been piloted in the 3 countries of sub-Saharan Africa in April 2019, with the total investment of around US$ 1 Bn. The program is partly funded by the Bill & Melinda Gates Foundation and African Research Centers. The vaccine is being developed by GSK at their lab in Belgium in collaboration with Path, which is an international non-profit organization. This ensures the cost effectiveness of the vaccine though it has taken around 30 years to develop at a cost of US$ 565 Mn. The company pledges not to make a profit from sales of the vaccine and adheres to the price range of around US$ 5 per shot.

Key features of the study:

  • This report provides in-depth analysis of the malaria vaccines and is its use, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period (2024 – 2027)
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global malaria vaccines market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, Distribution Channel strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Ltd., Sumaya Biotech and GenVec Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
  • The global malaria vaccines market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for malaria vaccines market, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the malaria vaccines market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Malaria Vaccines Market, By Vaccines Type:
    • Pre-Erythrocytic Vaccine
    • Erythrocytic Vaccine
    • Multi-antigen Vaccine
  • Global Malaria Vaccines Market, By Agent:
    • Plasmodium Falciparum
    • Plasmodium Vivax
  • Global Malaria Vaccines Market, By Distribution Channel:
    • Hospitals
    • Clinics
    • Community Centers
  • Global Malaria Vaccines Market, By Geography:
    • North America
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia-Pacific
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Vaccines Type:
        • Pre-Erythrocytic Vaccine
        • Erythrocytic Vaccine
        • Multi-antigen Vaccine
      • By Agent:
        • Plasmodium Falciparum
        • Plasmodium Vivax
      • By Distribution Channel:
        • Hospitals
        • Clinics
        • Community Centers
      • By Country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • GlaxoSmithKline plc *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Sanaria Inc.
    • Nobelpharma Co., Ltd.
    • Sumaya Biotech
    • GenVec, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Vaccines Type
      • Market Snippet By Agent
      • Market Snippet By Distribution Channel
      • Market Snippet By Geography
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • PEST Analysis
    • Key Market Developments
    • Product Pipeline Analysis
    • RTS, S Development Roadmap
  4. Global Malaria Vaccines Market, By Vaccines Type, 2024 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, 2024 - 2027
      • Segment Trends
    • Pre-Erythrocytic Vaccine
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
    • Erythrocytic Vaccine
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
    • Multi-antigen Vaccine
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
  5. Global Malaria Vaccines Market, By Agent, 2024 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, 2024 - 2027
      • Segment Trends
    • Plasmodium Falciparum
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
    • Plasmodium Vivax
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
  6. Global Malaria Vaccines Market, By Distribution Channel, 2024 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, 2024 - 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
    • Community Centers
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2024 - 2027, (US$ Million)
  7. Global Malaria Vaccines Market, By Geography, 2024 - 2027 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, For Regions, 2024 - 2027
    • North America
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • U.S.
        • Canada
    • Europe
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Share Analysis, By Country, 2024 and 2027 (%)
      • Y-O-Y Growth Analysis, By Country, 2024 - 2027
        • Northern Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sanaria Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Nobelpharma Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sumaya Biotech
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GenVec, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 24 figures on "Malaria Vaccines Market - Global forecast to 2027”.  

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.